WuXi Biologics to Acquire Pfizer's Pharma Plant in Hangzhou, China, an Industrial Info Market Brief

WuXi Biologics is preparing to acquire a 50,000-square-meter bio-pharmaceutical production base in Hangzhou, China, from Pfizer. The plant cost Pfizer $3.5 billion and began production in 2018, featuring an original solution production line and two preparation production lines.